Literature DB >> 19723641

Report from the Radiation Therapy Committee of the Southwest Oncology Group (SWOG): Research Objectives Workshop 2008.

Paul Okunieff1, Lisa A Kachnic, Louis S Constine, Clifton D Fuller, Laurie E Gaspar, Daniel F Hayes, Jean Hooks, Clifton Ling, Frank L Meyskens, Philip A Philip, David Raben, Stephen R Smalley, Gregory P Swanson, Beverly A Teicher, Charles R Thomas, Bhadrasain Vikram, Michael J Zelefsky, Laurence H Baker.   

Abstract

Strategic planning for the Radiation Therapy Committee of the Southwest Oncology Group (SWOG) is comprehensively evaluated every six years in an effort to maintain a current and relevant scientific focus, and to provide a standard platform for future development of protocol concepts. Participants in the 2008 Strategic Planning Workshop included clinical trial experts from multiple specialties, industry representatives from both pharmaceuticals and equipment manufacturers, and basic scientists. High-priority research areas such as image-guided radiation therapy for control of limited metastatic disease, analysis of biomarkers for treatment response and late toxicity, assessment of novel agents in combination with radiation, standardization of radiation target delineation, and the assessment of new imaging techniques to individualize cancer therapy, were discussed. Research priorities included clinical study designs featuring translational end points that identify patients most likely to benefit from combined modality therapy; intervention including combination radiation with standard chemotherapy; radiation with radiosensitizing molecular-targeted therapies; and stereotactic radiation for treatment of patients with regard to asymptomatic metastasis and radiation-induced tumor autoimmunity. The Committee concluded that the future research opportunities are among the most exciting to have developed in the last decade, and work is in progress to embark on these plans.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19723641      PMCID: PMC2978526          DOI: 10.1158/1078-0432.CCR-09-0357

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  89 in total

Review 1.  Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy.

Authors:  James L Tatum; Gary J Kelloff; Robert J Gillies; Jeffrey M Arbeit; J Martin Brown; K S Clifford Chao; J Donald Chapman; William C Eckelman; Anthony W Fyles; Amato J Giaccia; Richard P Hill; Cameron J Koch; Murali Cherukuri Krishna; Kenneth A Krohn; Jason S Lewis; Ralph P Mason; Giovanni Melillo; Anwar R Padhani; Garth Powis; Joseph G Rajendran; Richard Reba; Simon P Robinson; Gregg L Semenza; Harold M Swartz; Peter Vaupel; David Yang; Barbara Croft; John Hoffman; Guoying Liu; Helen Stone; Daniel Sullivan
Journal:  Int J Radiat Biol       Date:  2006-10       Impact factor: 2.694

2.  Design of multi-institutional and cooperative group studies of SBRT.

Authors:  Paul Okunieff
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

3.  Proceedings of the 3rd Acta Oncologica Symposium on Stereotactic Body Radiotherapy, June 15-17, 2006, Copenhagen, Denmark.

Authors: 
Journal:  Acta Oncol       Date:  2006       Impact factor: 4.089

4.  Statins, especially atorvastatin, may improve survival following brachytherapy for clinically localized prostate cancer.

Authors:  Mark A Moyad; Gregory S Merrick; Wayne M Butler; Kent E Wallner; Robert W Galbreath; Earnest G Butler; Zachariah A Allen; Edward Adamovich
Journal:  Urol Nurs       Date:  2006-08

Review 5.  Classic and novel roles of p53: prospects for anticancer therapy.

Authors:  José J Fuster; Silvia M Sanz-González; Ute M Moll; Vicente Andrés
Journal:  Trends Mol Med       Date:  2007-03-23       Impact factor: 11.951

6.  64Cu-azabicyclo[3.2.2]nonane thiosemicarbazone complexes: radiopharmaceuticals for PET of topoisomerase II expression in tumors.

Authors:  Lihui Wei; Johnny Easmon; Ravneet K Nagi; Brian D Muegge; Laura A Meyer; Jason S Lewis
Journal:  J Nucl Med       Date:  2006-12       Impact factor: 10.057

7.  Standard treatments induce antigen-specific immune responses in prostate cancer.

Authors:  Nancy J Nesslinger; Robert A Sahota; Brad Stone; Kayli Johnson; Navraj Chima; Caitlin King; Devon Rasmussen; Darcy Bishop; Paul S Rennie; Martin Gleave; Paul Blood; Howard Pai; Charles Ludgate; Brad H Nelson
Journal:  Clin Cancer Res       Date:  2007-03-01       Impact factor: 12.531

8.  ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.

Authors:  Cherrie K Donawho; Yan Luo; Yanping Luo; Thomas D Penning; Joy L Bauch; Jennifer J Bouska; Velitchka D Bontcheva-Diaz; Bryan F Cox; Theodore L DeWeese; Larry E Dillehay; Debra C Ferguson; Nayereh S Ghoreishi-Haack; David R Grimm; Ran Guan; Edward K Han; Rhonda R Holley-Shanks; Boris Hristov; Kenneth B Idler; Ken Jarvis; Eric F Johnson; Lawrence R Kleinberg; Vered Klinghofer; Loren M Lasko; Xuesong Liu; Kennan C Marsh; Thomas P McGonigal; Jonathan A Meulbroek; Amanda M Olson; Joann P Palma; Luis E Rodriguez; Yan Shi; Jason A Stavropoulos; Alan C Tsurutani; Gui-Dong Zhu; Saul H Rosenberg; Vincent L Giranda; David J Frost
Journal:  Clin Cancer Res       Date:  2007-05-01       Impact factor: 12.531

9.  Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models.

Authors:  Jeffrey M Albert; Carolyn Cao; Kwang Woon Kim; Christopher D Willey; Ling Geng; Dakai Xiao; Hong Wang; Alan Sandler; David H Johnson; Alexander D Colevas; Jennifer Low; Mace L Rothenberg; Bo Lu
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

Review 10.  PET imaging of tumour hypoxia.

Authors:  Anwar Padhani
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

View more
  5 in total

1.  Development of a software for quantitative evaluation radiotherapy target and organ-at-risk segmentation comparison.

Authors:  Jayashree Kalpathy-Cramer; Musaddiq Awan; Steven Bedrick; Coen R N Rasch; David I Rosenthal; Clifton D Fuller
Journal:  J Digit Imaging       Date:  2014-02       Impact factor: 4.056

2.  Prospective assessment of an atlas-based intervention combined with real-time software feedback in contouring lymph node levels and organs-at-risk in the head and neck: Quantitative assessment of conformance to expert delineation.

Authors:  Musaddiq Awan; Jayashree Kalpathy-Cramer; G Brandon Gunn; Beth M Beadle; Adam S Garden; Jack Phan; Emma Holliday; William E Jones; Elizabeth Maani; Abhilasha Patel; Jehee Choi; Virginia Clyburn; Bundhit Tantiwongkosi; David I Rosenthal; Clifton D Fuller
Journal:  Pract Radiat Oncol       Date:  2012-12-21

3.  A pilot prospective feasibility study of organ-at-risk definition using Target Contour Testing/Instructional Computer Software (TaCTICS), a training and evaluation platform for radiotherapy target delineation.

Authors:  Jayashree Kalpathy-Cramer; Steven D Bedrick; Kelly Boccia; Clifton D Fuller
Journal:  AMIA Annu Symp Proc       Date:  2011-10-22

4.  Targeting the epigenetics of the DNA damage response in breast cancer.

Authors:  M F Montenegro; R González-Guerrero; L Sánchez-del-Campo; A Piñero-Madrona; J Cabezas-Herrera; J N Rodríguez-López
Journal:  Cell Death Dis       Date:  2016-04-07       Impact factor: 8.469

5.  An in-silico quality assurance study of contouring target volumes in thoracic tumors within a cooperative group setting.

Authors:  Hesham Elhalawani; Baher Elgohari; Timothy A Lin; Abdallah S R Mohamed; Thomas J Fitzgerald; Fran Laurie; Kenneth Ulin; Jayashree Kalpathy-Cramer; Thomas Guerrero; Emma B Holliday; Gregory Russo; Abhilasha Patel; William Jones; Gary V Walker; Musaddiq Awan; Mehee Choi; Roi Dagan; Omar Mahmoud; Anna Shapiro; Feng-Ming Spring Kong; Daniel Gomez; Jing Zeng; Roy Decker; Femke O B Spoelstra; Laurie E Gaspar; Lisa A Kachnic; Charles R Thomas; Paul Okunieff; Clifton D Fuller
Journal:  Clin Transl Radiat Oncol       Date:  2019-01-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.